Reducing infectious complications after allogeneic stem cell transplant

References

• Tabbara IA, Zimmerman K, Morgan C, et al. Allogeneic hematopoietic stem cell transplantation: complications and results. Arch Intern Med. 2002;162(14):1558–1566.
   PubMed Web of Science ®Google Scholar
• Ferreira AM, Moreira F, Guimaraes T, et al. Epidemiology, risk factors and outcomes of multi-drugresistant bloodstream infections in haematopoietic stem cell transplant recipients: importance of previous gut colonization. J Hosp Infect. 2018;100(1):83–91.
   PubMed Web of Science ®Google Scholar
• Omer AK, Ziakas PD, Anagnostou T, et al. Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience. Biol Blood Marrow Transplant. 2013;19:1190–1196.
   PubMed Web of Science ®Google Scholar
• Piñana JL, Gómez MD, Pérez A, et al. Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: risk factors and mortality from pulmonary virus-bacterial mixed infections. Transpl Infect Dis. 2018;20(4):e12926.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study—sorveglianza epidemiologica infezioni fungine nelle emopatie maligne. Clin Infect Dis. 2007;45(9):1161–1170.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Raiola AM, Galaverna F, et al. Pre-engraftment bloodstream infections after allogeneic hematopoietic cell transplantation: impact of T cell-replete transplantation from a haploidentical donor. Biol Blood Marrow Transplant. 2018;24(1):109–118.
   PubMed Web of Science ®Google Scholar
• Einsele H, Bertz H, Beyer J, et al. Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2003;82(Suppl 2):S175–85.
   PubMedGoogle Scholar
• Hicheri Y, Einsele H, Martino R, et al. Environmental prevention of infection in stem cell transplant recipients: a survey of the infectious diseases working party of the European group for blood and marrow transplantation. Transpl Infect Dis. 2013;15(3):251–258.
   PubMed Web of Science ®Google Scholar
• Siegel JD, Rhinehart E, Jackson M, et al. Healthcare Infection Control Practices Advisory Committee. Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. 2007 [ updated 2019; cited 2020 Aug 20]. Available from: https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html
   Google Scholar
• Yokoe D, Casper C, Dubberke E, et al. Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated. Bone Marrow Transplant. 2009;44:495–497.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Schmidt-Hieber M, Bertz H, et al. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol. 2016;95:1435–1455.
   PubMed Web of Science ®Google Scholar
• Styczynski J, Tridello G, Donnelly JP, et al. Protective environment for hematopoietic cell transplant (HSCT) recipients: the infectious diseases working party EBMT analysis of global recommendations on health-care facilities. Bone Marrow Transplant. 2018;53(9):1131–1138.
   PubMed Web of Science ®Google Scholar
• Allegranzi B, Pittet D. Role of hand hygiene in healthcare associated infection prevention. J Hosp Infect. 2009;73(4):305–315.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56–e93.
   PubMed Web of Science ®Google Scholar
• Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant. 2009;15(10):1143–1238.
   Google Scholar
• Mackall C, Fry T, Gress R, et al. Background to hematopoietic cell transplantation, including post transplant immune recovery. Bone Marrow Transplant. 2009;44:457–462.
   PubMed Web of Science ®Google Scholar
• Dykewicz CA. Centers for disease control and prevention (U.S.); infectious diseases society of America; American Society of Blood and Marrow Transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33(2):139–144.
   PubMed Web of Science ®Google Scholar
• Blennow O, Ljungman P, Sparrelid E, et al. Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations. Transpl Infect Dis. 2014;16:106–114.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Del Bono V, Raiola AM, et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant. 2009;15:47–53.
   PubMed Web of Science ®Google Scholar
• Puerta-Alcalde P, Cardozo C, Marco F, et al. Changing epidemiology of bloodstream infection in a 25-years hematopoietic stem cell transplant program: current challenges and pitfalls on empiric antibiotic treatment impacting outcomes. Bone Marrow Transplant. 2020;55(3):603–612.
   PubMed Web of Science ®Google Scholar
• Balletto E, Mikulska M. Bacterial infections in hematopoietic stem cell transplant recipients. Mediterr J Hematol Infect Dis. 2015;7(1):e2015045.
   PubMedGoogle Scholar
• Mikulska M, Viscoli C, Orasch C, et al. Fourth European Conference on Infections in Leukemia Group ajvo EEIELN, ESGICH/ESCMID. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014;68(4):321–331.
   PubMed Web of Science ®Google Scholar
• Gudiol C, Garcia-Vidal C, Arnan M, et al. Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients. Bone Marrow Transplant. 2014;49(6):824–830.
   PubMed Web of Science ®Google Scholar
• Weisser M, Theilacker C, Tschudin Sutter S, et al. Hospital infection surveillance system for patients with haematologic/oncologic malignancies study group (ONKO-KISS). Secular trends of bloodstream infections during neutropenia in 15 181 haematopoietic stem cell transplants: 13-year results from a European multicentre surveillance study (ONKO-KISS). Clin Microbiol Infect. 2017;23(11):854–859.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Yue Y, Zhu L, et al. Epidemiology and microbiology of gram-positive bloodstream infections in a tertiary-care hospital in Beijing, China: a 6-year retrospective study. Antimicrob Resist Infect Control. 2018;7:107.
   PubMed Web of Science ®Google Scholar
• Mikulska V, Del Bono R, Prinapori L, et al. Risk factors for enterococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2010;12:505–512.
   PubMed Web of Science ®Google Scholar
• Benamu E, Deresinski S. Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention. F1000Res. 2018;7:3.
   PubMedGoogle Scholar
• Cohen N, Mihu CN, Seo SK, et al. Hematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(10):1337–1341.
   PubMed Web of Science ®Google Scholar
• Almyroudis NG, Osawa R, Samonis G, et al. Discontinuation of systematic surveillance and contact precautions for vancomycin-resistant enterococcus (VRE) and its impact on the incidence of VRE faecium bacteremia in patients with hematologic malignancies. Infect Control Hosp Epidemiol. 2016;37(4):398–403.
   PubMed Web of Science ®Google Scholar
• Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. Clin Microbiol Rev. 2014;27(4):870–926.
   PubMed Web of Science ®Google Scholar
• Collin BA, Leather HL, Wingard JR, et al. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis. 2001;33:947–953.
   PubMed Web of Science ®Google Scholar
• Averbuch D, Cordonnier C, Livermore D, et al. on behalf of ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica. 2013;98(12):1836–1847.
   PubMed Web of Science ®Google Scholar
• Engelhard D, Cordonnier C, Shaw PJ, et al. Infectious disease working party of the European bone marrow transplantation (IDWP-EBMT). Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol. 2002;117(2):444–450.
   PubMed Web of Science ®Google Scholar
• Martens P, Worm SW, Lundgren B, et al. Serotype-specific mortality from invasive streptococcus pneumoniaedisease revisited. BMC Infect Dis. 2004;30(4):21.
   Google Scholar
• Cordonnier C, Averbuch D, Maury S, et al. Pneumococcal immunization in immunocompromised hosts: where do we stand? Expert Rev Vaccines. 2014;13(1):59–74.
   PubMed Web of Science ®Google Scholar
• Chopra T, Alangaden GJ, Chandrasekar P. Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther. 2010;8(10):1113–1119.
   PubMed Web of Science ®Google Scholar
• Bruminhent J, Wang ZX, Hu C, et al. Clostridium difficile colonization and disease in patients undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(9):1329–1334.
   PubMed Web of Science ®Google Scholar
• Debast SB, Bauer MP, Kuijper EJ. European society of clinical microbiology and infectious diseases: update of the treatment guidance document for clostridium difficile infection. Clin Microbiol Infect. 2014;20(Suppl 2):1–26.
   PubMed Web of Science ®Google Scholar
• Gu SL, Chen YB, Lv T, et al. Risk factors, outcomes and epidemiology associated with clostridium difficile infection in patients with haematological malignancies in a tertiary care hospital in China. J Med Microbiol. 2015;64:209–216.
   PubMed Web of Science ®Google Scholar
• Girmenia C, Bertaina A, Piciocchi A, et al. Gruppo Italiano Trapianto di Midollo Osseo (GITMO) and Associazione Microbiologi Clinici Italiani (AMCLI). Incidence, risk factors and outcome of preengraftment gram-negative bacteremia after allogeneic and autologous hematopoietic stem cell transplantation: an Italian prospective multicenter survey. Clin Infect Dis. 2017;65(11):1884–1896.
   PubMed Web of Science ®Google Scholar
• Girmenia C, Rossolini GM, Piciocchi A, et al. Infections by carbapenem resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant. 2015;50(2):282–288.
   PubMed Web of Science ®Google Scholar
• Hauck CG, Chong PP, Miller MB, et al. Increasing rates of fluoroquinolone resistance in Escherichia coli isolated from the blood and urine of patients with hematologic malignancies and stem cell transplant recipients. Pathog Immun. 2016;1:234–242.
   PubMedGoogle Scholar
• Kjellander C, Bjorkholm M, Cherif H, et al. Hematological: low all-cause mortality and low occurrence of antimicrobial resistance in hematological patients with bacteremia receiving no antibacterial prophylaxis: A single-center study. Eur J Haematol. 2012;88(5):422–430.
   PubMed Web of Science ®Google Scholar
• Chong Y, Yakushiji H, Ito Y, et al. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis. 2011;15(4):e277–e281.
   PubMed Web of Science ®Google Scholar
• Vonberg RP, Gastmeier P. Hospital-acquired infections related to contaminated substances. J Hosp Infect. 2007;65:15–23.
   PubMed Web of Science ®Google Scholar
• Lowe C, Willey B, O’Shaughnessy A, et al. Outbreak of extended-spectrum b-lactamase-producing Klebsiella oxytoca infections associated with contaminated handwashing sinks. Emerg Infect Dis. 2012;18:1242–1247.
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Pagano L, Martino B, et al. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicenter prospective survey. Am J Hematol. 2014;91:1076–1081.
   Web of Science ®Google Scholar
• Calbo E, Freixas N, Xercavins M, et al. Foodborne nosocomial outbreak of SHV-1 and CTX-M-15-producing Klebsiella pneumoniae: epidemiology and control. Clin Infect Dis. 2011;52:743–749.
   PubMed Web of Science ®Google Scholar
• Averbuch D, Tridello G, Hoek J, et al. Antimicrobial resistance in gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the infectious diseases working party of the European bone marrow transplantation group. Clin Infect Dis. 2017;65:1819–1828.
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Pagano L, Candoni A, et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect. 2015;21:337–343.
   PubMed Web of Science ®Google Scholar
• Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98:1826–1835.
   PubMed Web of Science ®Google Scholar
• Kim SB, Min YH, Cheong JW, et al. Incidence and risk factors for carbapenem- and multidrug-resistant acinetobacter baumannii bacteremia in hematopoietic stem cell transplantation recipients. Scand J Infect Dis. 2014;46(2):81–88.
   PubMed Web of Science ®Google Scholar
• Robins-Browne RM, Rowe B, Ramsaroop R, et al. A hospital outbreak of multiresistant Salmonella typhimurium belonging to phage type 193. J Infect Dis. 1983;147:210–216.
   PubMed Web of Science ®Google Scholar
• NCCN clinical practice guidelines in oncology. Prevention and treatment of cancer-related infections. v. 2. 2020 [cited 2020 Aug 20]. Available from: www.nccn.org
   Google Scholar
• Cordonnier C, Einarsdottir S, Cesaro S, et al. European Conference on Infections in Leukaemia group. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(6):e200–e12.
   PubMed Web of Science ®Google Scholar
• Girmenia C, Raiola AM, Piciocchi A, et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: A prospective study of the gruppo italiano trapianto midollo osseo (GITMO). Biol Blood Marrow Transplant. 2014;20:872–880.
   PubMed Web of Science ®Google Scholar
• Sun Y, Meng F, Han M, et al. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study. Biol Blood Marrow Transplant. 2015;21:1117–1126.
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Upton A, Kirby KA, et al. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008;47:1041–1050.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis. 2010;50:1091–1100.
   PubMed Web of Science ®Google Scholar
• Atalla A, Garnica M, Maiolino A, et al. Risk factors for invasive mold diseases in allogeneic hematopoietic cell transplant recipients. Transpl Infect Dis. 2015;17(1):7–13.
   PubMed Web of Science ®Google Scholar
• Sun Y, Xu L, Liu D, et al. Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation. Clin Microbiol Infect. 2013;19:1029–1034.
   PubMed Web of Science ®Google Scholar
• Choi JK, Cho SY, Yoon SS, et al. Epidemiology and risk factors for invasive fungal diseases among allogeneic hematopoietic stem cell transplant recipients in Korea: results of “RISK” study. Biol Blood Marrow Transplant. 2017;23:1773–1779.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Raiola AM, Bruno B, et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant. 2009;44(6):361–370.
   PubMed Web of Science ®Google Scholar
• Marr K, Bowden RA. Fungal infections in patients undergoing blood and marrow transplantation. Transpl Infect Dis. 1999;1:237–246.
   PubMedGoogle Scholar
• Penack O, Tridello G, Hoek J, et al. Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the infectious diseases and acute leukemia working parties. Bone Marrow Transplant. 2016;51(3):418–423.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Chamilos G, Lewis RE, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer. 2007;110:1303–1306.
   PubMed Web of Science ®Google Scholar
• Verma A, Wüthrich M, Deepe G, et al. Adaptive immunity to fungi. Cold Spring Harb Perspect Med. 2014;5(3):a019612.
   PubMed Web of Science ®Google Scholar
• Cunha C, Aversa F, Lacerda JF, et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med. 2014;370:421–432.
   PubMed Web of Science ®Google Scholar
• Cunha C, Di Ianni M, Bozza S, et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood. 2010;116:5394–5402.
   PubMed Web of Science ®Google Scholar
• Martino R, Parody R, Fukuda T, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the infectious diseases working party of the Euro. Blood. 2006;108:2928–2936.
   PubMed Web of Science ®Google Scholar
• Stanzani M, Lewis RE, Fiacchini M, et al. A risk prediction score for invasive mold disease in patients with hematological malignancies. PloS One. 2013;8(9):e75531.
   PubMed Web of Science ®Google Scholar
• Girmenia C, Barosi G, Piciocchi A, et al. Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 2014;20:1080–1088.
   PubMed Web of Science ®Google Scholar
• Thursky K, Byrnes G, Grigg A, et al. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;34(2):115–121.
   PubMed Web of Science ®Google Scholar
• Vokurka S, Bystrická E, Svoboda T, et al. The availability of HEPA-filtered rooms and the incidence of pneumonia in patients after haematopoietic stem cell transplantation (HSCT): results from a prospective, multicentre, eastern European study. J Clin Nurs. 2014;23:1648–1652.
   PubMed Web of Science ®Google Scholar
• Kanamori H, Rutala WA, Sickbert-Bennett EE, et al. Review of fungal outbreaks and infection prevention in healthcare settings during construction and renovation. Clin Infect Dis. 2015;61:433–444.
   PubMed Web of Science ®Google Scholar
• Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545–1552.
   PubMed Web of Science ®Google Scholar
• Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Eng J Med. 1992;326(13):845–851.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med. 2003;138:705–714.
   PubMed Web of Science ®Google Scholar
• Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103(4):1527–1533.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–359.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Eng J Med. 2007;356(4):335–347.
   PubMed Web of Science ®Google Scholar
• Cho SY, Lee DG, Choi SM, et al. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: A single-centre retrospective study in Korea and clinical considerations. Mycoses. 2015;58:565–571.
   PubMed Web of Science ®Google Scholar
• Kung HC, Johnson MD, Drew RH, et al. Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study. Cancer Med. 2014;3:667–673.
   PubMed Web of Science ®Google Scholar
• Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111–5118.
   PubMed Web of Science ®Google Scholar
• Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155:318–327.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Duarte RF, Haider S, et al. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother. 2016;71(3):718–726.
   PubMed Web of Science ®Google Scholar
• Leclerc E, Combarel D, Uzunov M, et al. Prevention of invasive aspergillus fungal infections with the suspension and delayed-release tablet formulations of posaconazole in patients with haematologic malignancies. Sci Rep. 2018;8(1):1681.
   PubMedGoogle Scholar
• Cornely OA, Robertson MN, Haider S, et al. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother. 2017 Dec 1;72(12):3406–3413.
   PubMed Web of Science ®Google Scholar
• Busca A, Candoni A, Audisio E, et al. Long-lasting protective effect of posaconazole prophylaxis in patients with acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22:2214–2219.
   PubMedGoogle Scholar
• van Burik JA, Ratanatharathorn V, Stepan DE, et al. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39(10):1407–1416.
   PubMed Web of Science ®Google Scholar
• Xhaard A, Porcher R, Bergeron A, et al. Primary antifungal prophylaxis with micafungin after allogeneic hematopoietic stem cell transplantation: a monocentric prospective study. Ann Hematol. 2019;98:1033–1035.
   PubMed Web of Science ®Google Scholar
• Epstein DJ, Seo SK, Huang YT, et al. Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study. J Infect. 2018;77:227–234.
   PubMed Web of Science ®Google Scholar
• Fontana L, Perlin DS, Zhao Y, et al. Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients. Clin Infect Dis. 2020;70(5)723–730.
   PubMed Web of Science ®Google Scholar
• Maertens JA, Girmenia C, Brüggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73:3221–3230.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24:e1–e38.
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR, Denning DW, et al. Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63:433–442.
   PubMed Web of Science ®Google Scholar
• Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 2009;43(10):757–770.
   PubMed Web of Science ®Google Scholar
• Hill G, Chauvenet AR, Lovato J, et al. Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukemia. Pediatrics. 2005;116:e525–9.
   PubMed Web of Science ®Google Scholar
• Steer CB, Szer J, Sasadeusz J, et al. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant. 2000;25:657–664.
   PubMed Web of Science ®Google Scholar
• Safdar A, Rodriguez GH, De Lima MJ, et al. Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996–2005. Medicine (Baltimore). 2007;86:324–333.
   PubMed Web of Science ®Google Scholar
• Tomonari A, Iseki T, Takahashi S, et al. Varicella-zoster virus infection in adult patients after unrelated cord blood transplantation: a single institute experience in Japan. Br J Haematol. 2003;122:802–805.
   PubMed Web of Science ®Google Scholar
• Kim DH, Messner H, Minden M, et al. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pretransplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis. 2008;10:90–98.
   PubMed Web of Science ®Google Scholar
• Marin M, Guris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56:1–40.
   PubMedGoogle Scholar
• Dagnew AF, Ilhan O, Lee WS, et al. Immunogenicity and safety of adjuvanted recombinant zoster vaccine in adults with hematological malignancies. A phase 3 randomized clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;9:988–1000.
   Google Scholar
• Ljungman P, de la Camara R, Robin C, et al. 2017 European Conference on Infections in Leukaemia group. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260–e272.
   PubMed Web of Science ®Google Scholar
• Green ML, Leisenring W, Stachel D, et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:1887–1899.
   Google Scholar
• Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011;11:284–292.
   PubMed Web of Science ®Google Scholar
• Ljungman P. The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell transplantation. Curr Opin Hematol. 2014;21:466–469.
   PubMed Web of Science ®Google Scholar
• Beck JC, Wagner JE, DeFor TE, et al. Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2010;16:215–222.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006;91:78–83.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2004;103:2003–2008.
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Labopin M, Beelen D, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood. 2013;122:3359–3364.
   PubMed Web of Science ®Google Scholar
• Nichols WG, Price TH, Gooley T, et al. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood. 2003;101:4195–4200.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Larsson K, Kumlien G, et al. Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors. Scand J Infect Dis. 2002;34:347–350.
   PubMed Web of Science ®Google Scholar
• Mainou M, Alahdab F, Tobian AA, et al. Reducing the risk of transfusion-transmitted cytomegalovirus infection: a systematic review and meta-analysis. Transfusion. 2016;56:1569–1580.
   PubMed Web of Science ®Google Scholar
• Aabb CTMC, Heddle NM, Boeckh M, et al. AABB Committee Report: reducing transfusion-transmitted cytomegalovirus infections. Transfusion. 2016;56:1581–1587.
   PubMed Web of Science ®Google Scholar
• Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet. 1994;343:749–753.
   PubMed Web of Science ®Google Scholar
• Ljungman P, de La Camara R, Milpied N, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood. 2002;99:3050–3056.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, doubleblind trial. Ann Intern Med. 1993;118:179–184.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Yeager AM, Chandrasekar PH, et al. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis. 2003;36:749–758.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017 Dec 21;377(25):2433–2444.
   PubMed Web of Science ®Google Scholar
• Chen K, Cheng MP, Hammond SP, et al. Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. Blood Adv. 2018;2(16):2159–2175.
   PubMed Web of Science ®Google Scholar
• Girmenia C, Lazzarotto T, Bonifazi F, et al. Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies. Clin Transplant. 2019;33(10):e13666.
   PubMed Web of Science ®Google Scholar
• Zerr DM, Corey L, Kim HW, et al. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40:932–940.
   PubMed Web of Science ®Google Scholar
• Ogata M, Kikuchi H, Satou T, et al. Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. J Infect Dis. 2006;193:68–79.
   PubMed Web of Science ®Google Scholar
• Sashihara J, Tanaka-Taya K, Tanaka S, et al. High incidence of human herpesvirus 6 infection with a high viral load in cord blood stem cell transplant recipients. Blood. 2002;100:2005–2011.
   PubMed Web of Science ®Google Scholar
• Ward KN, Hill JA, Hubacek P, et al. 2017 European Conference on Infections in Leukaemia (ECIL). Guidelines from the 2017 European Conference on Infections in Leukaemia for management of HHV-6 infection in patients with hematologic malignancies and after hematopoietic stem cell transplantation. Haematologica. 2019 Nov;104(11):2155–2163.
   PubMed Web of Science ®Google Scholar
• Zerr DM, Boeckh M, Delaney C, et al. HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(11):1700–1708.
   PubMed Web of Science ®Google Scholar
• Dulery R, Salleron J, Dewilde A, et al. Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study. Biol Blood Marrow Transplant. 2012;18(7):1080–1089.
   PubMed Web of Science ®Google Scholar
• Olson AL, Dahi PB, Zheng J, et al. Frequent human herpervirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin. Biol Blood Marrow Transplant. 2014;20(6):787–793.
   PubMed Web of Science ®Google Scholar
• Ogata M, Satou T, Kadota J, et al. Human herpesvirus 6 (HHV-6) reactivation and HHV-6 enecephalitis after allogeneic hematopoietic cell transplantation: a multicenter, prospective study. Clin Infect Dis. 2013;57(5):671–681.
   PubMed Web of Science ®Google Scholar
• Styczynski J, van der Velden W, Fox CP, et al. Management od Epstein-Barr Virus infections and post-tranplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101(7):803–811.
   PubMed Web of Science ®Google Scholar
• Fujimoto A, Hiramoto N, Yamasaki S, et al. Risk factors and predictive scoring system for post-transplant, lymphoproliferative disorder after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:1441–1449.
   PubMedGoogle Scholar
• Dominietto A, Tedone E, Soracco M, et al. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transplant. 2012;47(1):101–106.
   PubMed Web of Science ®Google Scholar
• Peffault de Latour R, Chevret S, Jubert C, et al. Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study. Blood. 2018;132:750–754.
   PubMed Web of Science ®Google Scholar
• Lazzarotto T, Chiereghin A, Piralla A, et al. Cytomegalovirus and Epstein-Barr Virus DNA kinetics in whole blood and plasma of allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2018;24:1699–1706.
   PubMedGoogle Scholar
• Coppoletta S, Tedone E, Galano B, et al. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(6):901–907.
   PubMed Web of Science ®Google Scholar
• Meerbach A, Wutzler P, Häfer R, et al. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J Med Virol. 2008;80(3):441–454.
   PubMed Web of Science ®Google Scholar
• Gruhn B, Meerbach A, Häfer R, et al. Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;31(11):1023–1025.
   PubMed Web of Science ®Google Scholar
• Heslop HE, Slobod KS, Pule MA. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115:925–935.
   PubMed Web of Science ®Google Scholar
• Gerdemann U, Keirnan JM, Katari UL, et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012;20(8):1622–1632.
   PubMed Web of Science ®Google Scholar
• Garcia-Cadenas I, Castillo N, Martino R, et al. Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab. Bone Marrow Transplant. 2015;50(4):579–584.
   PubMed Web of Science ®Google Scholar
• Sanz J, Arango M, Senent L, et al. EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. Bone Marrow Transplant. 2014;49(3):397–402.
   PubMed Web of Science ®Google Scholar
• Cohen JM, Cooper N, Chakrabarti S, et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma. 2007;48(2):256–269.
   PubMed Web of Science ®Google Scholar
• Uhlin M, Wikell H, Sundin M, et al. Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014;99(2):346–352.
   PubMed Web of Science ®Google Scholar
• Sundin M, Le Blanc K, Ringden O, et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica. 2006;91(8):1059–1067.
   PubMed Web of Science ®Google Scholar
• Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113(20):4992–5001.
   PubMed Web of Science ®Google Scholar
• Omar H, Hagglund H, Gustafsson-Jernberg A, et al. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transpl Infect Dis. 2009;11(5):393–399.
   PubMed Web of Science ®Google Scholar
• Matthes-Martin A, Feuchtinger T, Shaw PJ, et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis. 2012;14:555–563.
   PubMed Web of Science ®Google Scholar
• Ohrmalm L, Lindblom A, Omar H, et al. Evaluation of a surveillance strategy for early detection of adenovirus by PCR of peripheral blood in hematopoietic SCT recipients: incidence and outcome. Bone Marrow Transplant. 2011;46(2):267–272.
   PubMed Web of Science ®Google Scholar
• Walls T, Hawrami K, Ushiro-Lumb I, et al. Adenovirus infection after pediatric bone marrow transplantation: is treatment always necessary? Clin Infect Dis. 2005;40(9):1244–1249.
   PubMed Web of Science ®Google Scholar
• Lion T, Baumgartinger R, Watzinger F, et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood. 2003;102(3):1114–1120.
   PubMed Web of Science ®Google Scholar
• van Tol MJ, Kroes AC, Schinkel J, et al. Adenovirus infection in paediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery. Bone Marrow Transplant. 2005;36(1):39–50.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 2002;100:1619–1627.
   PubMed Web of Science ®Google Scholar
• Kampmann B, Cubitt D, Walls T, et al. Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. Br J Haematol. 2005;130:595–603.
   PubMed Web of Science ®Google Scholar
• Myers GD, Krance RA, Weiss H, et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant. 2005;36:1001–1008.
   PubMed Web of Science ®Google Scholar
• La Rosa AM, Champlin RE, Mirza N, et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis. 2001;32:871–876.
   PubMed Web of Science ®Google Scholar
• Erard V, Huang ML, Ferrenberg J, et al. Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease. Clin Infect Dis. 2007;45:958–965.
   PubMed Web of Science ®Google Scholar
• Feuchtinger T, Lucke J, Hamprecht K, et al. Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2005;128:503–509.
   PubMed Web of Science ®Google Scholar
• Myers GD, Bollard CM, Wu MF, et al. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39:677–686.
   PubMed Web of Science ®Google Scholar
• Raboni SM, Nogueira MB, Tsuchiya LR, et al. Respiratory tract viral infections in bone marrow transplant patients. Transplantation. 2003;76(1):142–146.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Dykewicz CA, Longworth DL, et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematol Am Soc Hematol Educ Program. 2001;1:392–421.
   PubMedGoogle Scholar
• Lehners N, Schnitzler P, Geis S, et al. Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit. Bone Marrow Transplant. 2013;48(12):1548–1553.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Chevret S, Legrand M, et al. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med. 2003;139(1):8–18.
   PubMed Web of Science ®Google Scholar
• Norlin AC, Sairafi D, Mattsson J, et al. Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transplant. 2008;41(3):267–273.
   PubMed Web of Science ®Google Scholar
• Choi SM, Boudreault AA, Xie H, et al. Differenced in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood. 2011;117:5050–5056.
   PubMed Web of Science ®Google Scholar
• Ljungman P, de la Camara R, Perez-Beroff I, et al. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplantat recipients. Haematologica. 2011;96:1231–1235.
   PubMed Web of Science ®Google Scholar
• Nichols WG, Guthrie KA, Corey I, et al. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis. 2004;39:1300–1306.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2001;28(5):479–484.
   PubMed Web of Science ®Google Scholar
• Schiffer JT, Kirby K, Sandmaier B, et al. Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica. 2009;94(8):1101–1108.
   PubMed Web of Science ®Google Scholar
• Khanna N, Steffen I, Studt JD, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2009;11(2):100–105.
   PubMed Web of Science ®Google Scholar
• Boudreault AA, Xie H, Leisenring W, et al. Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus. Biol Blood Marrow Transplant. 2011;17(7):979–986.
   PubMed Web of Science ®Google Scholar
• Engelhard D, Mohty B, de la Camara R, et al. European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transpl Infect Dis. 2013;15:219–232.
   PubMed Web of Science ®Google Scholar
• Engelhard D, Nagler A, Hardan I, et al. Antibody responde to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant. 1993;11:1–5.
   PubMed Web of Science ®Google Scholar
• Fukatsu Y, Nagata Y, Adachi M, et al. Serum IgM levels independently predict immune response to influenza vaccine in long-term survivors vaccinated at 1 years after undergoing allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2017;105:638–645.
   PubMed Web of Science ®Google Scholar
• Mothy B, Bel M, Vukicevic M, et al. Graft-versus-host disease is the major determinant of humoral responses to the As03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipient. Haematologica. 2011;96:896–904.
   PubMed Web of Science ®Google Scholar
• Natori Y, Humar A, Lipton J, et al. A pilot randomized trials of adjuvanted influenza vaccine in adult allogeneic hetaopoietic stem cell transplant recipients. Bone Marrow Transplant. 2017;52:1016–1021.
   PubMed Web of Science ®Google Scholar
• Issa NC, Marty FM, Gagne LS, et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011;17:434–438.
   PubMed Web of Science ®Google Scholar
• Weigt SS, Gregson AL, Deng JC, et al. Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. Semin Respir Crit Care Med. 2011;32:471–493.
   PubMed Web of Science ®Google Scholar
• Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood. 2011;117:2755–2763.
   PubMed Web of Science ®Google Scholar
• Martino R, Porras RP, Rabella N, et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant. 2005;11:781–796.
   PubMed Web of Science ®Google Scholar
• Avetisyan G, Mattsson J, Sparrelid E, et al. Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome. Transplantation. 2009;88:1222–1226.
   PubMed Web of Science ®Google Scholar
• Hirsch HH, Martino R, Ward KN, et al. Fourth European Conference on Infections in Leukemia (ECIL-4): guidelined for diagnosis and treatment of human Respiratory Syncytial Virus, Parainfluenza virus, Metapneumovirus, Rhinovirus, and Coronavirus. Clin Infect Dis. 2013;56(2):258–266.
   PubMed Web of Science ®Google Scholar
• Peck AJ, Englund JA, Kuypers J, et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood. 2007;110:1681–1688.
   PubMed Web of Science ®Google Scholar
• Mallet V, van Bömmel F, Doerig C, et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis. 2016;16(5):606–617.
   PubMed Web of Science ®Google Scholar
• Hammond SP, Borchelt AM, Ukomadu C, et al. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:1049–1059.
   PubMed Web of Science ®Google Scholar
• Onozawa M, Hashino S, Izumiyama K, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation. 2005;79:616–619.
   PubMed Web of Science ®Google Scholar
• Gentile G, Antonelli G. HBV reactivation in patients undergoing hematopoietic stem cell transplantation: a narrative review. Viruses. 2019;11:1049.
   Web of Science ®Google Scholar
• Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31:2765–2772.
   PubMed Web of Science ®Google Scholar
• Koenecke C, Pischke S, Beutel G, et al. Hepatitis E virus infection in a hematopoietic stem cell donor. Bone Marrow Transplant. 2014;49:159–160.
   PubMed Web of Science ®Google Scholar
• Suneetha PV, Pischke S, Schlaphoff V, et al. Hepatitis E virus (HEV)-specifi c T-cell responses are associated with control of HEV infection. Hepatology. 2012;55:695–708.
   PubMed Web of Science ®Google Scholar
• Ghez D, Nicand E, Ferré V, et al. Allogenic bone marrow transplantation with a donor presenting with an acute hepatitis A. J Hepatol. 2001;34:625–630.
   PubMed Web of Science ®Google Scholar
• Rauff B, Idrees M, Shah SA, et al. Hepatitis associated aplastic anemia: a review. Virol J. 2011;8:87.
   PubMed Web of Science ®Google Scholar
• McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255–267.
   PubMed Web of Science ®Google Scholar
• Coronavirus disease COVID-19: EBMT recommendations. [cited 2020 Aug 24]. Available from: www.ebmt.org
   Google Scholar
• Coronavirus disease - 2019 (COVID-19) and supply of substances of human origin in EU/EEA. [cited 2020 Aug 24]. Available from: www.ecdc.europa.eu.
   Google Scholar
• Peled JU, Gomes ALC, Devlin SM, et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. N Engl J Med. 2020;382:822–834.
   PubMed Web of Science ®Google Scholar